Orchestra BioMed
Manufacturing · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
150 Union Square Dr, New Hope, Pennsylva...Phone Number
(215) 862-5797Website
www.orchestrabiomed.comRevenue
$32.7 MillionStock Symbol
OBIOIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Orchestra BioMed
Orchestra BioMed Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.Explore more
Orchestra BioMed Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Orchestra BioMed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Orchestra BioMed had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Orchestra BioMed
Orchestra BioMed, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Orchestra BioMed has recently received funding, and reach out quickly before it becomes old news!
Check out if Orchestra BioMed is spiking on competitors!
Product Launch: Get notified when Orchestra BioMed launches new products
Funding: Get notified immidiatlly once Orchestra BioMed has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Orchestra BioMed recently announced quarterly report
Recommended Actions
Find VP level buyers at Orchestra BioMed
Find 2 more new buyers
Compare Similar Companies to Orchestra BioMed
Compare insights from companies similar to Orchestra BioMed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$97.4M
201-500
Public
$237.2M
1997
John DesjarlaisExecutive Vice President & Research & Scientific Chief & Officer
Company Profile Activity
Activity Insights
Orchestra BioMed is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Orchestra BioMed is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Orchestra BioMed.
Orchestra BioMed financials insights
Gather financial insights about Orchestra BioMed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Private Equity
$41M
2019
Other Financing Round
$34M
Debt
$20M
2022
Series D
$110M
2025
Unspecified
$70M
2026
Unspecified
$20M
Orchestra BioMed Tech Stack
A closer look at the technologies used by Orchestra BioMed
Most Recent Scoops
Project
Orchestra BioMed is conducting the BACKBEAT global pivotal trial for AVIM therapy in partnership with Medtronic, enrolling up to 316 patients across sites in the US, Europe, and China, with enrollment nearing completion and targeted for the end of next quarter. The trial randomizes patients with uncontrolled hypertension receiving Medtronic dual-chamber pacemakers on a blinded basis, with primary endpoints assessed at 3 months measuring 24-hour ambulatory blood pressure superiority and freedom from unanticipated serious adverse device events, plus additional data through 12 months.
Medical Research, Clinical Operations
Project
Orchestra BioMed has developed a proprietary extended-release sirolimus formulation for the Virtue SAB program, designed to enable focal, localized, extended drug release delivered as a large liquid dose through a balloon. In a published large-number porcine coronary artery study, Virtue SirolimusEFR levels were nearly 10-fold higher than those achieved by a stent through the 30-day period.
Medical Research, Pharmaceuticals
Project
Orchestra BioMed has reported that full field stimulus threshold testing in its LCA5 trial demonstrated more than one log unit improvement in retinal sensitivity in adults and one and a half log unit improvement in children across both red and blue wavelengths a response considered a theoretical maximum by clinicians leading to the decision to advance the trial into a pivotal component at the low dose.
Medical Research, Pharmaceuticals, Clinical Operations
Partnership
Orchestra BioMed has established an exclusive licensing arrangement with Medtronic for AVIM therapy, backed by an IP estate of over 120 issued patents globally, making Orchestra BioMed the only program in clinical and regulatory development for this therapy and positioning Medtronic as the sole commercial partner with access to this offering.
Partnership
Project
Medical Research, Pharmaceuticals, Clinical Operations
Orchestra BioMed News & Media
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on June 1, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 85,500 shares of the Company’s common stock to fiveOrchestra BioMed to Participate in the Jefferies Global Healthcare Conference
NEW HOPE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will be participating in the Jefferies Global Healthcare Conference.Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
NEW HOPE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2026, and provided a business update highlighting momentum across the Company’s pivotal-stage programs for Atrioventricular Interval Modulation (“AVIM”) Therapy and Virtue® SirolimusOrchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
NEW HOPE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced an update to the overall clinical and regulatory timeline for the BACKBEAT Trial evaluating Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) in pacemaker-indicated patients with unco
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Orchestra BioMed
Sign Up For FreeTo access detailed company insights
Orchestra BioMed Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosc... Read More
